Nucleic acid testing guidance
This article was originally published in The Gray Sheet
Blood banks should implement recommendations from FDA 1guidance on NAT in whole blood and blood components (including source plasma and source leukocytes) within six months of Oct. 28 publication in the Federal Register, the agency advises. Pertaining to nucleic acid tests for HIV-1 and hepatitis C virus, the document updates an April 2002 draft guidance, combining it with a December 2001 guidance on NAT testing in plasma. The consolidated guidance features recommendations for donor screening and reporting requirements for licensed blood and plasma establishments. The new document also addresses product labeling and disposition...
You may also be interested in...
The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.
Swissmedic says its good manufacturing practice certificates remain valid for longer than companies might assume. Separately, it is giving companies more time to conduct nitrosamine-related risk evaluations.
Stada has appointed a head of digital communications; PGEU elects new chair and vice-chair; and the new UK health claims committee unveils its first members.